Anwita Biosciences, Inc. is a clinical stage biopharmaceutical company based in San Carlos, CA, specializing in the discovery and development of optimized immunotherapeutics for cancer and autoimmune diseases. Their core technology integrates structure-guided cytokine evolution and target-based protein evolution, enabling the development of fully optimized cytokine fusions with superior therapeutic potential. With a focus on improving the lives of patients, Anwita Biosciences is advancing their product pipeline of improved cytokines and tumor-targeting antibody drug conjugates, including their lead product, Exenokine-21, which has been accepted for clinical studies by regulatory authorities in China and the US.
Utilizing their expertise in cancer immunotherapy, bioinformatics, and target-based protein evolution, Anwita Biosciences aims to deliver transformative treatment options for patients with cancer and autoimmune diseases. Their unique product portfolio includes half-life extended cytokines, immune cell- or tumor cell-targeting cytokines, and bi-functional cytokines. Through ongoing clinical trials and partnerships, Anwita Biosciences is dedicated to developing novel immune therapies that have the potential to significantly impact the field of oncology and autoimmune disease treatment.
Generated from the website